NSX Thursday, 11/07/19 12:59:30 PM Re: Firedog01890 post# 322 Post # of 369 $ARQL.....in apparent response to a just-released abstract on blood cancer candidate ARQ 531, a reversible BTK inhibitor, that will be presented at ASH next month. https://ash.confex.com/ash/2019/webprogram/Paper127260.html I believe people are comparing this BTK inhibitor Phase ! dosing and safety to Lilly more favorable safety profile There is more there......for example a lower dose of 65 mg is now being tested and safer...more to follow My research and my opinion. My opinions is not a recommendation to buy or sell a security. Your decision whether or not to make a purchase should be based on your own due diligence.